In contrast with the B-ALL CD4/CD8 ratio median of 0.6 (range, 0.3–1.9), the DLBCL products had an increased ratio of 2.3 (range, 0.5–3.2) (Figure 1H). This evidence concerns the gene CD4 and diffuse large B-cell lymphoma.